Related Experiment Videos
Pulse cyclophosphamide therapy for inflammatory bowel disease.
Zsolt Barta1, László Tóth, Margit Zeher
13rd Department of Medicine, Faculty of Medicine, Medical and Health Science Centre, University of Debrecen, H-4012 Debrecen, Moricz Zs. krt 22, Hungary. barta@iiibel.dote.hu
World Journal of Gastroenterology
|March 15, 2006
Summary
Intravenous cyclophosphamide pulse therapy effectively induced remission in patients with refractory inflammatory bowel disease (IBD). This aggressive immunosuppressive treatment was well-tolerated and led to long-lasting remission in most participants.
Area of Science:
- Gastroenterology
- Immunosuppressive Therapy
- Inflammatory Bowel Disease Research
Background:
- Refractory inflammatory bowel disease (IBD) poses significant treatment challenges.
- Steroid-refractory IBD requires alternative therapeutic strategies.
Purpose of the Study:
- To evaluate the efficacy of intravenous cyclophosphamide pulse therapy for patients with moderate to severe, steroid-refractory IBD.
- To assess the safety and tolerability of this treatment regimen.
Main Methods:
- A cohort of eight patients with steroid-refractory IBD (four ulcerative colitis, four Crohn's disease) received six monthly cycles of intravenous cyclophosphamide (800 mg).
- Disease activity and remission status were monitored throughout the treatment period.
Main Results:
- Remission was achieved in most patients after the second or third cyclophosphamide pulse, with decreased disease activity.
- All Crohn's disease patients and 75% of ulcerative colitis patients achieved complete remission.
- No significant side effects or toxicity were observed; remission was maintained long-term.
Conclusions:
- Intravenous cyclophosphamide pulse therapy demonstrates significant efficacy in inducing and maintaining remission in refractory IBD.
- The treatment is well-tolerated, suggesting its potential as an aggressive immunosuppressive option for select IBD patients.
- Further controlled studies are warranted to confirm these findings and establish cyclophosphamide's role in IBD management.